Abstract

The specific aim is to stimulate and facilitate the development of cancer control research within the defined region of Northern California and Northern Nevada by maintaining and strengthening the effective consortium established in 1974 as the Northern California Cancer Program. Within the first decade of its existence, this unique consortium cancer center has already brought together a diverse group of individuals and institutions with a common interest in cancer control. These institutions and individuals include universities, private research foundations, state health departments, regional public health agencies, health maintenance organizations, community-based organizations, physicians, scientists, other professionals and interested lay persons. This proposal will support cancer control research activities in four progammatic areas: 1) multi-disciplinary/multi-institutional laboratory research with direct applications to cancer treatment, cancer epidemiology and cancer prevention; 2) multi-disciplinary and multi-institutional cancer clinical trials research with direct applications to reducing morbidity and mortality among patients already diagnosed as having cancer; 3) multi-disciplinary and multi-institutional epidemiologic research focused upon populations within the defined region of Northern California and Northern Nevada; and 4) multi-disciplinaryt and multi-institutional cancer detection, cancer prevention and cancer education research focused upon populations within this same defined region.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA019408-10
Application #
3101624
Study Section
(SRC)
Project Start
1983-07-01
Project End
1989-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
10
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Northern California Cancer Center
Department
Type
DUNS #
City
Fremont
State
CA
Country
United States
Zip Code
94538

  Publications

Hoshino, T; Ahn, D; Prados, M D et al. (1993) Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer 53:550-5
Cohen, M B; Haber, M M; Holly, E A et al. (1991) Cytologic criteria to distinguish hepatocellular carcinoma from nonneoplastic liver. Am J Clin Pathol 95:125-30
West, D W; Slattery, M L; Robison, L M et al. (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85-94
Larson, D A; Gutin, P H; Leibel, S A et al. (1990) Stereotaxic irradiation of brain tumors. Cancer 65:792-9
Kelly, J W; Holly, E A; Shpall, S N et al. (1989) The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol 30:1-8
Harnly, M E; Swan, S H; Holly, E A et al. (1988) Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS) Am J Epidemiol 128:261-7
Bottles, K; Chan, J S; Holly, E A et al. (1988) Cytologic criteria for fibroadenoma. A step-wise logistic regression analysis. Am J Clin Pathol 89:707-13
Mohle-Boetani, J C; Grosser, S; Whittemore, A S et al. (1988) Body size, reproductive factors, and breast cancer survival. Prev Med 17:634-42
Carlson, R W; Williams, R D; Billingham, M E et al. (1987) Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group. Cancer Treat Rep 71:767-8
Carlson, R W; Billingham, M E; Kohler, M et al. (1987) Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study. Cancer Treat Rep 71:427-8

Showing the most recent 10 out of 15 publications